reports
Dime Community Bancshares Declares Quarterly Cash Dividend for Common ...
Dime Community Bancshares Declares Quarterly Cash Dividend for Common Stock HAUPPAUGE, N.Y., June 26, 2025 (GLOBE NEWSWIRE) -- Dime Community Bancshares, Inc. (Nasdaq: DCOM) (the “Company”) announced that its Board of Directors declared a quarterly cash dividend of $0.25 per share of Common Stock, payable on July 24, 2025 to common stockholders of record as of July 17, 2025. The Company continues its trend of uninterrupted dividends. ABOUT DIME COMMUNITY BANCSHARES, INC. Dime Community Bancshares, Inc. is the holding company for Dime Community Bank, a New York State-chartered trust comp...
Dime Sponsors 10th New York City Small Business Challenge
Dime Sponsors 10th New York City Small Business Challenge HAUPPAUGE, N.Y., June 25, 2025 (GLOBE NEWSWIRE) -- Dime Community Bancshares, Inc. (the “Company” or “Dime”) (NASDAQ: DCOM), the parent company of Dime Community Bank (the “Bank”), announced that the Bank, in partnership with 1010 WINS, hosted the Dime Community Bank $10K Small Business Challenge in Manhattan for the 10th consecutive year. This year’s challenge saw a record number of applicants from across New York City competing for a $10,000 grant to support their new business growth. ABOUT DIME COMMUNITY BANCSHARES, INC. ...
Outlook Therapeutics to Participate in a Virtual Investor Lunch Break ...
Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event Live webcast on Wednesday, June 25th at 12:00 PM ET ISELIN, N.J., June 18, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it will participate in a on Wednesday, June 25, 2025 at 12:00 PM ET. As part of the event, Lawrence Kenyon, Chief Financial Officer and Interim Chief Executive Officer, Jeff Evanson, Chief Commercial Officer and Jedd Comiskey, Senior VP – Head of Europe...
Kroll Bond Rating Agency Revises Dime Community Bancshares, Inc.’s Rat...
Kroll Bond Rating Agency Revises Dime Community Bancshares, Inc.’s Ratings Outlook from “Stable” to “Positive” HAUPPAUGE, N.Y., June 17, 2025 (GLOBE NEWSWIRE) -- Dime Community Bancshares, Inc. (the “Company” or “Dime”) (NASDAQ: DCOM), the parent company of Dime Community Bank (the “Bank”), announced that Kroll Bond Rating Agency (“KBRA”), in a report dated June 17, 2025, revised its ratings outlook from “Stable” to “Positive.” Kroll’s deposit and senior unsecured debt rating for Dime Community Bank is BBB+. According to the KBRA report, the revision of the Outlook to “Positive” primaril...
Dime Announces Approval of Lakewood, NJ Branch by the NJ Department of...
Dime Announces Approval of Lakewood, NJ Branch by the NJ Department of Banking and Insurance HAUPPAUGE, N.Y., June 17, 2025 (GLOBE NEWSWIRE) -- Dime Community Bancshares, Inc. (NASDAQ: DCOM) (the “Company” or “Dime”), the parent company of Dime Community Bank (the “Bank”), announced it has received approval from the New Jersey Department of Banking and Insurance to open a branch location at 500 Boulevard of Americas in Lakewood, New Jersey. As previously announced, the Federal Reserve Bank of New York and the New York State Department of Financial Services have also approved the branch lo...
Dime Continues to Execute on Growth Plan with the Hire of Shawn Gines
Dime Continues to Execute on Growth Plan with the Hire of Shawn Gines HAUPPAUGE, N.Y., June 16, 2025 (GLOBE NEWSWIRE) -- As part of the continued execution of its growth plan, Dime Community Bancshares, Inc. (NASDAQ: DCOM) (the “Company” or “Dime”), the parent company of Dime Community Bank (the “Bank”), announced today that Shawn Gines will join Dime as Executive Vice President, Corporate and Specialty Finance. Mr. Gines will play an integral role in the continued buildout and diversification of Dime’s commercial lending businesses, including growing Dime’s presence with corporate clien...
Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevac...
Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD ISELIN, N.J., June 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the Scottish Medicines Consortium (SMC) acceptance of LYTENAVA™ (bevacizumab gamma) for use within NHS Scotland for the treatment of wet age-related macular degeneration (wet AMD). LYTENAVA™ (bevacizumab gamma) is the first and only licensed ophthalmic formulation of bevacizum...
Dime Announces Receipt of Federal Reserve and NYDFS Approvals for Lake...
Dime Announces Receipt of Federal Reserve and NYDFS Approvals for Lakewood, NJ Branch Location HAUPPAUGE, N.Y., June 02, 2025 (GLOBE NEWSWIRE) -- Dime Community Bancshares, Inc. (NASDAQ: DCOM) (the “Company” or “Dime”), the parent company of Dime Community Bank (the “Bank”), announced it has received approvals from the Federal Reserve Bank of New York and the New York State Department of Financial Services to open a branch location in Lakewood, New Jersey. The branch will be located at 500 Boulevard of the Americas, Lakewood, New Jersey, pending approval from the New Jersey Department of...
Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevaci...
Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK)2.8 million injections of repackaged off-label bevacizumab in Europe each year1 ISELIN, N.J., June 02, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that LYTENAVA™ (b...
Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offeri...
Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering ISELIN, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the pricing of an underwritten public offering of 9,285,714 shares of its common stock, together with accompanying warrants to purchase 18,571,428 shares of its common stock. The combined public offering price of common stock and accompanying warrant is $1.40. The common stock is being sold ...
Outlook Therapeutics® Announces Proposed Public Offering of Common Sto...
Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants ISELIN, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has commenced an underwritten public offering of its common stock and accompanying warrants exercisable for shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be complet...
Outlook Therapeutics Reports Financial Results for Second Quarter Fisc...
Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update LYTENAVA™ (bevacizumab gamma) on track for planned first commercial launches in Germany and the United Kingdom (UK) in Q2 CY2025Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025 in the United States ISELIN, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today reported financial results for the second quarter of fiscal year 2025 ...
Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Tri...
Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit Data from Phase 1 clinical trial of ATH-1105 in healthy volunteers showed a favorable safety and tolerability profile; dose proportional pharmacokinetics and CNS penetration support continued clinical development On-track to enable initiation of a clinical trial in ALS patients in late 2025 BOTHELL, Wash., May 13, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to r...
Athira Pharma Reports First Quarter 2025 Financial Results and Pipelin...
Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS); full healthy volunteer data expected in 2H25 On-track to enable dosing ALS patients in late 2025 BOTHELL, Wash., May 09, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the quarter ...
Dime Adds Fund Finance Banking Vertical
Dime Adds Fund Finance Banking Vertical Michael Watts Appointed Group Leader and Head of Fund Finance HAUPPAUGE, N.Y., May 05, 2025 (GLOBE NEWSWIRE) -- As part of the continued execution of its growth plan, Dime Community Bancshares, Inc. (NASDAQ: DCOM) (the “Company” or “Dime”), the parent company of Dime Community Bank (the “Bank”), announced the launch of a new fund finance vertical. Led by Michael Watts, the Fund Finance vertical will provide customized fund-level financing to the private equity industry and expand Dime's coverage across this ecosystem. Watts, who will be based in M...
Solomon Ponniah to Join Dime as Group Leader
Solomon Ponniah to Join Dime as Group Leader Dime Continues to Execute on Growth Plan and NYC Metro Buildout HAUPPAUGE, N.Y., April 30, 2025 (GLOBE NEWSWIRE) -- Dime Community Bancshares, Inc. (NASDAQ: DCOM) (the “Company” or “Dime”), the parent company of Dime Community Bank (the “Bank”) announced that it has hired Solomon Ponniah as Senior Vice President and Group Leader. Solomon comes to Dime with over 15 years of experience in Commercial Lending, most recently as Director of Business Banking at Popular Bank. “I am excited to join Dime and be a part of their growth story. Dime’s a...
Dime Community Bancshares Declares Quarterly Cash Dividend for Series ...
Dime Community Bancshares Declares Quarterly Cash Dividend for Series A Preferred Stock HAUPPAUGE, N.Y., April 24, 2025 (GLOBE NEWSWIRE) -- Dime Community Bancshares, Inc. (Nasdaq: DCOM, DCOMP and DCOMG) (the “Company”) announced that its Board of Directors declared a quarterly cash dividend of $0.34375 per share on the Company’s 5.50% Fixed-Rate Non-Cumulative Perpetual Preferred Stock, Series A, payable on May 15, 2025 to holders of record as of May 8, 2025. ABOUT DIME COMMUNITY BANCSHARES, INC. Dime Community Bancshares, Inc. is the holding company for Dime Community Bank, a New York...
Dime Community Bancshares, Inc. Reports First Quarter 2025 EPS of $0.4...
Dime Community Bancshares, Inc. Reports First Quarter 2025 EPS of $0.45; Adjusted EPS of $0.57 Continued Growth in Core Deposits and Business Loans On a Year-over-Year Basis Net Interest Margin Expands by 16 basis points on a Linked Quarter Basis to 2.95% HAUPPAUGE, N.Y., April 22, 2025 (GLOBE NEWSWIRE) -- Dime Community Bancshares, Inc. (NASDAQ: DCOM) (the “Company” or “Dime”), the parent company of Dime Community Bank (the “Bank”), today reported net income available to common stockholders of $19.6 million for the quarter ended March 31, 2025, or $0.45 per diluted common share, compa...
Dime Announces Plans to Enter Lakewood, New Jersey
Dime Announces Plans to Enter Lakewood, New Jersey HAUPPAUGE, N.Y., April 17, 2025 (GLOBE NEWSWIRE) -- Dime Community Bancshares, Inc. (Nasdaq: DCOM) (the “Company” or “Dime”), the parent company of Dime Community Bank (the “Bank”), today announced that its Board of Directors has approved a plan to expand into Lakewood, New Jersey. A location for a full-service, free-standing branch has been identified. Management expects construction of the branch to take place in the second half of 2025, simultaneous with the regulatory approval process. The current plan is for a branch opening in e...
Dime Continues to Execute Growth Plan With Hire of Deposit-Focused Gro...
Dime Continues to Execute Growth Plan With Hire of Deposit-Focused Group George Taitt to join as Group Director, Amy Grandy to join as Associate Group Director HAUPPAUGE, N.Y., April 10, 2025 (GLOBE NEWSWIRE) -- Dime Community Bancshares, Inc. (NASDAQ: DCOM) (the “Company” or “Dime”), the parent company of Dime Community Bank (the “Bank”) announced that it has hired a deposit-focused Group that will cover the Queens market. The Group will be led by George Taitt and Amy Grandy. The Group was previously employed with the former Signature Bank and its successor, Flagstar Bank. Stuart H. L...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.